Innovator’s Pitch Challenge

Vote for Us

Interested in Connecting? Please contact:
Joshua McClure
CEO
joshua@maxwellbiosciences.com

Message the company or request a 1:1 meeting here

The company has shown promising results in mice treated intranasally with Maxwell’s lead product candidates against refractory, polymicrobial airway infections. Large animal studies are planned for Q1 2022, and an FDA Investigational New Drug filing is planned for 4Q23. Follow-on oncological, viral, fungal and bacterial infectious disease targets are planned through licensing/partnering.

Pitch Video

Slide Deck